(Q43048075)

12 November 2017

Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy (English)

1 reference

12 November 2017

4

Stefan Zeuzem

1 reference

12 November 2017

Jörn Lötsch

1

0 references

Alfred Ultsch

6

object named as

Alfred Ultsch

1 reference

12 November 2017

Wolf Peter Hofmann

2

1 reference

12 November 2017

Christina Schlecker

3

1 reference

12 November 2017

Gerd Geisslinger

5

1 reference

12 November 2017

Alexandra Doehring

7

1 reference

12 November 2017

1 December 2011

1 reference

12 November 2017

1 reference

12 November 2017

12

1 reference

12 November 2017

12

1 reference

12 November 2017

1729-1740

1 reference

Hepatitis C pharmacogenetics: state of the art in 2010.

12 November 2017

1 reference

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

Genomewide association studies and assessment of the risk of disease

21 January 2018

1 reference

Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip

21 January 2018

1 reference

Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses

21 January 2018

1 reference

Hepatitis C infection and the patient with end-stage renal disease

21 January 2018

1 reference

Hepatitis C treatment: current and future perspectives

21 January 2018

1 reference

Development of novel therapies for hepatitis C.

21 January 2018

1 reference

Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene

21 January 2018

1 reference

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.

21 January 2018

1 reference

Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)

21 January 2018

1 reference

IFN-lambda: novel antiviral cytokines

21 January 2018

1 reference

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

21 January 2018

1 reference

Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells.

21 January 2018

1 reference

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

Lambda interferon inhibits hepatitis B and C virus replication

21 January 2018

1 reference

Interferon type I gene expression in chronic hepatitis C.

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection

21 January 2018

1 reference

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection

21 January 2018

1 reference

Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.

21 January 2018

1 reference

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

21 January 2018

1 reference

The metabolism of ribavirin in erythrocytes and nucleated cells

21 January 2018

1 reference

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance

21 January 2018

1 reference

Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.

21 January 2018

1 reference

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

21 January 2018

1 reference

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

21 January 2018

1 reference

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C.

21 January 2018

1 reference

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

21 January 2018

1 reference

HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.

21 January 2018

1 reference

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

21 January 2018

1 reference

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

21 January 2018

1 reference

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

Assessing the quality of case-control association studies on the genetic basis of sepsis

21 January 2018

1 reference

The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene

21 January 2018

1 reference

Quantitative in vitro and in vivo characterization of the human P32T mutant ITPase

21 January 2018

1 reference

Functional study of the P32T ITPA variant associated with drug sensitivity in humans.

21 January 2018

1 reference

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

21 January 2018

1 reference

Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop

21 January 2018

1 reference

Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.

21 January 2018

1 reference

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation

21 January 2018

1 reference

Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.

21 January 2018

1 reference

Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon

21 January 2018

1 reference

Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1.

21 January 2018

1 reference

Mendelian proportions in a mixed population

21 January 2018

1 reference

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.

21 January 2018

1 reference

IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection

21 January 2018

1 reference

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

21 January 2018

1 reference

Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.

21 January 2018

1 reference

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

21 January 2018

1 reference

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

21 January 2018

1 reference

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

Screening for IL28B gene variants identifies predictors of hepatitis C therapy success

21 January 2018

1 reference

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

21 January 2018

1 reference

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort.

21 January 2018

1 reference

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

21 January 2018

1 reference

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

21 January 2018

1 reference

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

21 January 2018

1 reference

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

21 January 2018

1 reference

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

21 January 2018

1 reference

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

21 January 2018

1 reference

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.11.99

1 reference

12 November 2017

1 reference